Window Therapeutics
Boston, US · Founded 2021 · Delaware corporation · 1 known investors
Window Therapeutics develops cancer therapeutics using its proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology, which aims to widen the therapeutic window of drugs by increasing their activity against cancer cells while reducing systemic toxicity to healthy tissue. The company targets blood and solid cancers and offers its platform for optimizing partner drug candidates across preclinical to late-stage development.
BiotechDeep TechHealthtech
Founders & leadership
JL
James LuDirector
JJ
Jeremiah JohnsonDirector
LL
Lusong LuoDirector
KA
Kenneth AndersonDirector
CH
Chih-Kao HuExecutive Officer, Director
KC
Kenneth C. AndersonProfessor, Researcher and Clinician, Harvard Medical School & DFCI
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$7.5MraisedOct 2023 · 10 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James LuDirector
- Jeremiah JohnsonDirector
- Lusong LuoDirector
- Kenneth AndersonDirector
- Chih-Kao HuExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Minimum investment
- $50K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.